SCHEMBL18486378

SCHEMBL18486378

O=C(O)c1cccc(-c2ncnc3[nH]cnc23)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.49
MAP2K4 P45985 2/20 0.47
MAPK1 P28482 1/20 0.47
MAPKAPK3 Q16644 1/20 0.47
MAPK6 Q16659 1/20 0.47
NT5E P21589 1/20 0.45
NT5C2 P49902 1/20 0.45
KMO O15229 2/20 0.45
LIMK1 P53667 1/20 0.44
CD74 P04233 1/20 0.43
MIF P14174 1/20 0.43
CSNK2A2 P19784 2/20 0.43
CSNK2B P67870 2/20 0.43
AXL P30530 2/20 0.42
LDHA P00338 2/20 0.42
EGFR P00533 2/20 0.42
CSNK2A1 P68400 1/20 0.41
LDHB P07195 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2938674 0.80 JAK2 (0.54) NT5C2
SCHEMBL26434474 0.80 TOP2A (0.68) TOP2ACSNK2A2CSNK2BEGFRCSNK2A1
SCHEMBL18066303 0.78 PRKCI (0.47) MAP2K4MAPK1NT5ENT5C2LIMK1
SCHEMBL18486287 0.78 TOP2A (0.62) TOP2AMAP2K4MAPK1MAPKAPK3MAPK6
SCHEMBL12676222 0.77 NEK2 (0.53) MAP2K4NT5ENT5C2
SCHEMBL4939143 0.77 RPS6KB1 (0.52) TOP2AMAPK1LDHALDHB
SCHEMBL16619108 0.76 NT5C2 (0.69) NT5ENT5C2EGFR
SCHEMBL18066309 0.75 PIM1 (0.47) MAPK1NT5ENT5C2LIMK1AXL
SCHEMBL3928813 0.74 AKT2 (0.67)
SCHEMBL18066326 0.74 GSK3B (0.41) MAPK1NT5ENT5C2LIMK1AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 TOP2A 409/4885MAP2K4 4712/4885MAPK1 3838/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 TOP2A 438/4885MAP2K4 4714/4885MAPK1 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.